<DOC>
	<DOCNO>NCT01978782</DOCNO>
	<brief_summary>Depression common mental health disorder among HIV-patients . Recognizing treat depression important order improve quality life health outcome live HIV . In clinical practice selective serotonin reuptake inhibitor ( SSRIs ) use frequently HIV patient depressive symptom . A complicate factor concomitant use antiretroviral agent antidepressant therapy occurrence drug-drug interaction . Citalopram see one preferred SSRIs HIV-infected patient citalopram relatively favourable drug interaction profile compare SSRIs . Raltegravir HIV-1 integrase inhibitor frequently use antiretroviral agent combination tenofovir/emtricitabine HIV-patients . Raltegravir show sustained antiretroviral activity , generally well tolerated little propensity interact drug inhibit induce CYP450 enzyme . Theoretically , clinically relevant drug interaction expect raltegravir citalopram raltegravir CYP2D6 substrate thus affect possible inhibition CYP2D6 citalopram . Raltegravir metabolize UGT citalopram know influence UGT . A possible interaction may occur inhibition P-gp mediate transport raltegravir citalopram . However , even drug interaction expect theoretically , may recommend collect sufficient clinical evidence support hypothesis unexpected interaction raltegravir observe past . In order able recommend raltegravir citalopram concomitant use , pharmacokinetic study healthy volunteer propose .</brief_summary>
	<brief_title>Pharmacokinetic Drug-drug Interaction Study Between RaltEgravir CITALopram Healthy Subjects ( RECITAL ) .</brief_title>
	<detailed_description />
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>1 . Subject least 18 old 55 year screen . 2 . Subject smoke 10 cigarette , 2 cigar , 2 pipe per day least 3 month prior Day 1 . 3 . Subject Quetelet Index ( Body Mass Index ) 18 30 kg/m2 , extremes include . 4 . Subject able willing sign Informed Consent Form prior screen evaluation . 5 . Subject good ageappropriate health condition establish medical history , physical examination , electrocardiography , result biochemistry , haematology urinalysis test within 4 week prior Day 1 . Results biochemistry , haematology urinalysis test within laboratory 's reference range . If laboratory result within reference range , subject include condition Investigator judge deviation clinically relevant . This clearly record . 6 . Subject normal blood pressure pulse rate , accord Investigator 's judgement . 1 . Documented history sensitivity/idiosyncrasy medicinal product excipients . 2 . Positive HIV test . 3 . Positive hepatitis B C test . 4 . Pregnant female ( confirm hCG test perform less 4 week day 1 ) breastfeed female . Female subject childbearing potential without adequate contraception , e.g . hysterectomy , bilateral tubal ligation , ( nonhormonal ) intrauterine device , total abstinence , double barrier method , two year postmenopausal . They must agree take precaution order prevent pregnancy throughout entire conduct study . 5 . Therapy drug ( two week precede Day 1 ) , except acetaminophen . 6 . Relevant history presence pulmonary disorder ( especially COPD ) , cardiovascular disorder , neurological disorder ( especially seizures migraine ) , psychiatric disorder , gastrointestinal disorder , renal hepatic disorder , hormonal disorder ( especially diabetes mellitus ) , coagulation disorder . 7 . Relevant history presence QT syndrome , prolong QTc time , bradycardia , hypokalaemia hypomagnesaemia , recent acute myocardial infarction , uncompensated heart failure . 8 . Relevant history current condition might interfere drug absorption , distribution , metabolism excretion . 9 . History current abuse drug , alcohol solvent . 10 . Inability understand nature extent study procedure require . 11 . Participation drug study within 60 day prior Day 1 . 12 . Donation blood within 60 day prior Day 1 . 13 . Febrile illness within 3 day Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>raltegravir</keyword>
	<keyword>citalopram</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>drug-drug interaction</keyword>
</DOC>